Sanofi SA
Company Profile
Business description
Sanofi develops and markets drugs with a concentration in vaccines, immunology, oncology, cardiovascular disease, diabetes, and over-the-counter treatments. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing about 30% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Contact
46, Avenue de la Great Army
Paris75017
FRAT: +33 153774000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
82,878
Stocks News & Analysis
markets
Globalisation declining? Not in investor portfolios
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,203.90 | 28.80 | 0.35% |
CAC 40 | 7,597.85 | 61.59 | 0.82% |
DAX 40 | 22,365.23 | 122.78 | 0.55% |
Dow JONES (US) | 40,275.75 | 162.25 | 0.40% |
FTSE 100 | 8,444.11 | 28.86 | 0.34% |
HKSE | 21,971.96 | 8.78 | -0.04% |
NASDAQ | 17,370.07 | 12.87 | -0.07% |
Nikkei 225 | 35,839.99 | 134.25 | 0.38% |
NZX 50 Index | 12,098.89 | 81.05 | 0.67% |
S&P 500 | 5,532.05 | 6.84 | 0.12% |
S&P/ASX 200 | 7,997.10 | 28.90 | 0.36% |
SSE Composite Index | 3,288.41 | 6.65 | -0.20% |